



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



Role of Trimetazidine in Prevention of Coronary No Reflow in Patients with ST Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

A Thesis

*Submitted for Partial Fulfillment of M.D. Degree
in Cardiology*

Presented By

Moheb Morad Sobhy

Cardiologist(MSc), Ain Shams University

Under Supervision of

Prof. Dr. Ahmed Abd El Rahman Sharf EL Din

*Professor of Cardiology Department,
Ain Shams University*

Dr. Haytham Galal Mohamed Helmy

*Assistant Professor of Cardiology Department,
Ain Shams University*

Dr. Hazem Mohamed Khorshid

*Assistant Professor of Cardiology Department,
Ain Shams University*

*Faculty of Medicine
Ain Shams University*

2021

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سَبِّحْ اِنَّكَ لَا تَعْلَمُ لَنَا
اِلَّا مَا عَلَّمْتَنَا اِنَّكَ اَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Ahmed Abd El Rahman Shaf El Din**, Professor of Cardiology Department, Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Haytham Galal Mohamed Helmy**, Assistant Professor of Cardiology Department, Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Hazem Mohamed Khorshid**, Assistant Professor of Cardiology Department, Ain Shams University, for his great help, active participation and guidance.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Mohab Morad Sobhy

List of Contents

Title	Page No.
List of Tables	i
List of Figures	ii
List of Abbreviations	iii
Introduction.....	1
Aim of the Work	4
<u>Review of Literature:</u>	
Myocardial Infarction	5
Coronary No-Reflow	13
Trimetazidine	22
Subjects and Methods.....	29
Results.....	41
Discussion	56
Summary	66
Limitations of the Study	69
Conclusion	70
Recommendations.....	71
References.....	72
Arabic Summary.....	

List of Tables

Table No.	Title	Page No.
Table (1):	Demographic characteristics of the Studied Groups.....	41
Table (2):	Risk factors distribution among the studied patients.	42
Table (3):	Pain to Door time (PTD).....	43
Table (4):	Baseline laboratory profile.....	43
Table (5):	ECG and Cardiac enzymes (baseline and after 24 hours)	44
Table (6):	STEMI territory, culprit vessel, site of occlusion, thrombus burden, TIMI flow pre PPCI and KILLIP classification.	46
Table (7):	PCI technique and stent size.	47
Table (8):	Coronary no-reflow post PPCI.	48
Table (9):	Echocardiographic assessment 1 day after PPCI.	48
Table (10):	Echocardiographic assessment after 1 month.	50
Table (11):	Clinical follow up of patients in both groups for 1 month.....	52
Table (12):	Percentage of changes regarding baseline and after 1 day (ECG, cardiac enzymes and troponin) & after 1 day and after 1 month echocardiographic parameters in both groups.....	53

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Leading cause of death globally	6
Figure (2):	Pathogenesis of MI type 1	7
Figure (3):	Pathogenesis of MI type 2	8
Figure (4):	Pathogenesis of No-Reflow	14
Figure (5):	Therapies of No-Reflow Targeted to Main Pathogenetic Mechanisms ..	21
Figure (6):	Structure of TMZ.	23
Figure (7):	Cardiac Metabolism in Normal Conditions	24
Figure (8):	Metabolic Alterations during Sustained Period of Ischaemia ...	25
Figure (9):	Mechanism of action of trimetazidine.	26
Figure (10):	ST segment elevation in ECG after 24 hours in both groups. ...	45
Figure (11):	E/E' day after PPCI.....	49
Figure (12):	GLS in both groups after 1 month.	51
Figure (13):	Diastolic function by TDI (E/E') after 1 month.	51
Figure (14):	Percentage of change of LV ejection fraction in both groups by Echo after 1 month.....	54
Figure (15):	Percentage of descent of CK total in both groups in 24 hours.....	55
Figure (16):	Percentage of change in resolution of ST segment elevation in ECG in both groups after 24 hours.	55

